Phosphodiesterase type 5 (PDE 5) is the major cGMP hydrolyzing enzyme in penile corpus cavernosum and is an important regulator of nitric oxide-mediated smooth muscle relaxation. The critical role of PDE 5 in penile erection and the recent availability of specific and potent inhibitors of PDE 5 have enabled the development of effective oral treatment strategies that have been widely accepted by both health-care professionals and the lay public. This article examines the correlation between the available biochemical and clinical data for the PDE 5 inhibitors sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra).
Introduction

Guanosine 3
0 ,5 0 -cyclic monophosphate (cGMP) is an important mediator of smooth muscle relaxation and has been shown to be a key molecular regulator of penile tumescence. Intracellular cGMP concentrations are strictly controlled by the action of guanylyl cyclases and cGMP-specific phosphodiesterases. [1] [2] [3] [4] A well-defined biochemical pathway leading to penile erection involves the binding of nerve-or endothelium-derived nitric oxide to the heme moiety of soluble guanylyl cyclase within the vascular smooth muscle of the resistance arteries and the trabeculae of the corpora cavernosa. 5 This activation of guanylyl cyclase by nitric oxide catalyzes the formation of cGMP from GTP. Elevated levels of intracellular cGMP lead to the activation of cGMP-specific phosphodiesterases which hydrolyze cGMP to 5 0 -GMP. The degradation of cGMP by phosphodiesterases is one of the main mechanisms by which the nitric oxide signal transduction pathway is terminated within smooth muscle cells.
In all, 11 main types of phosphodiesterases (some types with multiple isoforms) have been identified to date. 6, 7 Each type of phosphodiesterase has differing substrate specificities based upon their ability to discriminate between cGMP and adenosine 3 0 ,5 0 -cyclic monophosphate (cAMP). Furthermore, the activity of different phosphodiesterases may be modulated by varying mechanisms. Thus, regulation of cyclic nucleotide metabolism depends on the specific expression profile of the various phosphodiesterase types in a given tissue. Although several different types of phosphodiesterases have been identified within penile cavernosal tissue, human trabecular smooth muscle cells express phosphodiesterase type 5 (PDE 5) as the major cGMP hydrolyzing enzyme. 8, 9 PDE 5 was initially identified as the major cGMP binding protein in bovine lung and later characterized as a cGMP-binding, cGMP-specific phosphodiesterase. [10] [11] [12] The purified protein is a homodimer of 99.6 kDa subunits and binds two zinc atoms per monomer which are necessary for catalysis. 13 PDE 5 has two allosteric sites for cGMP binding. Occupancy of these sites is necessary for phosphorylation of PDE 5 which has been shown to occur via protein kinase G-dependent mechanisms. 14, 15 In experiments using recombinant bovine PDE 5, phosphorylation of the enzyme has been shown to increase the affinity of the allosteric binding sites for cGMP and enhance catalytic activity by 50-70%. 16 Recent equilibrium radioligand binding studies indicate that sildenafil binds to the catalytic site of PDE 5 with high affinity (0.83-12 nM) and limited capacity (0.6 mol/mol-subunit). 17 The presence of up to 10 mM of cGMP enhanced the affinity of [ 3 H]silde-nafil for PDE 5, most likely through interactions at the allosteric binding sites. These data suggest that sildenafil may potentiate its own action by inhibiting PDE 5 and causing the elevation of intracellular cGMP levels, which further increases the affinity of sildenafil for PDE 5. Whether this phenomenon is specific for sildenafil or present as a general mechanism of potentiation for any PDE 5 inhibitor remains to be seen. The critical role of PDE 5 in penile erectile physiology and the synthesis and identification of specific and potent inhibitors of PDE 5 have enabled the development of effective oral treatment strategies that have been widely accepted by both healthcare professionals and the lay public. This brief review will examine the correlation between the available biochemical and clinical data for the PDE 5 inhibitors sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis) (see Figure 1 for chemical structures).
Potency and efficacy of PDE 5 inhibitors
The potency and efficacy of any therapeutic agent is dependent upon numerous factors. For orally administered PDE 5 inhibitors, these factors include: (1) dissolution and absorption time (t max ), (2) solubility and plasma protein associations, (3) tissue and cell permeability, (4) binding and dissociation rates of inhibitors to PDE 5 (K d , IC 50 and K i ), and (5) metabolism and clearance (t 1/2 ). Any of these factors can significantly influence clinical measures of potency and efficacy in patients and may lead to inconsistencies between clinical and laboratory data. In laboratory studies, parameters of affinity and enzyme inhibitory capacity are the most common means of comparing drug potency. For the purposes of this discussion, the pharmacological definition of potency will be employed. Potency is inversely proportional to the concentration of drug required to inhibit an enzyme (eg the lower the IC 50 or K i , the greater the potency).
As can be seen in Figure 2 , the ranking of IC 50 values was identical in two different studies utilizing purified PDE 5 preparations. Vardenafil was found to be the most potent, followed by sildenafil and tadalafil. 18, 19 (E Gbekor, personal communication, 2002) Similar differences in inhibitory potency were observed in comparing sildenafil and vardenafil incubated with human cavernosal tissue extracts. 20 These differences in potency between sildenafil and vardenafil were maintained in functional assays that measured cGMP accumulation in cultured smooth muscle cells and erectile function in both anesthetized and conscious rabbits. [20] [21] [22] With the exception of IC 50 determinations, direct head-to-head comparative studies for all three PDE 5 inhibitors have not been reported. However, the 18 Gresser and Gleiter 19 and E Gbekor, personal communication.
available preclinical in vitro and in vivo data suggest that vardenafil is a more potent inhibitor of PDE 5 than either sildenafil or tadalafil. Additional differences between the three PDE 5 inhibitors can be seen from the pharmacokinetic data (Table 1) . 23, 24 While the dose for sildenafil was five times higher than either tadalafil or vardenafil, the most notable distinctions are the longer half-life (t 1/2 ) of tadalafil and the lower maximal plasma concentration (C max ) of vardenafil. It is likely that the prolonged half-life of tadalafil results in its accumulation and leads to a higher plasma concentration than vardenafil although equal doses of each inhibitor were administered.
The time of onset of action for each PDE 5 inhibitor is not readily available. However, in a small study of 17 patients administered 50 mg of sildenafil after visual sexual stimulation, the median onset time to achieve penile erection with greater than 60% rigidity (assessed by RigiScan) was 27 min after dosing. 25 In studies using successful intercourse completion as the primary measure of efficacy, 20 mg of tadalafil was observed to be effective as early as 16 min after dosing in 32% of men (vs 15% for placebo). 26 Although no comparable published data are available for vardenafil in humans, it is reasonable to assume from the t max that a significant proportion of men taking vardenafil would experience enhanced erectile function within 30 min. The efficacy of these compounds does not appear to be significantly affected by food or alcohol intake, since most clinical trials did not restrict these parameters.
By virtue of its earlier availability, the greatest amount of clinical data has been accumulated for sildenafil. It is estimated that more than 13 million patients have been treated with Viagra worldwide. 27 In a meta-analysis of 27 clinical trials (randomized, placebo-controlled studies lasting at least 7 days) involving 6659 men, Fink et al 28 reported that sildenafil administration resulted in a significant increase in the mean score for question #4 on the International Index of Erectile Function (IIEF) and in the percentage of successful intercourse attempts per patient. For the 25 mg dose, a 1.5-fold increase was observed over placebo, whereas a 2.5-fold increase over placebo was observed for the 50 and 100 mg doses. While individual studies have indicated varying extents of enhancement in erectile function, all have reported significant increases in the percentage of successful intercourse attempts and the percentage of patients who responded 'yes' to the global assessment question (GAQ)
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While the clinical data for vardenafil and tadalafil are not as extensive as sildenafil, similar outcome measures indicate that both PDE 5 inhibitors are effective in treating men diagnosed with erectile dysfunction. 24, [30] [31] [32] [33] [34] Separate studies indicate that vardenafil significantly improves erectile function in men with type I or type II diabetes mellitus and also in men with a history of radical prostatectomy. 35 In a recently published phase 3, randomized, double-blind, placebo-controlled, multicenter study performed at sites in the US and Canada, vardenafil significantly increased the percentage of successful intercourse attempts by 50-100%, depending on dose. 32 Similar degrees of enhancement were reported for the percentage of patients responding positively to the GAQ. In addition, the effectiveness of vardenafil at the midpoint of the study (12 weeks) persisted through the end of the treatment period (26 weeks).
An important caveat in interpreting the data from this vardenafil study is that patients with a history of failing sildenafil therapy were specifically excluded. In the group of patients who experienced improved erections with vardenafil, 71% reported previously using sildenafil successfully. The exclusion of sildenafil nonresponders in this study may increase the percentage of patients responding positively to vardenafil. On the other hand, it is likely that the patients enrolled into the study, on average, had less severe erectile dysfunction. This would cause elevated placebo or baseline values and potentially lead to smaller degrees of enhancement with drug administration (Table 2 ). This may be the reason for the reported 50-100% enhancement in successful intercourse attempts for vardenafil vs the 150-250% increase reported for sildenafil. It should be noted that similar exclusion criteria were used for the clinical assessment of tadalafil 33 and published data indicate similar trends (ie higher scores for placebo and active drug with smaller relative increases when compared to sildenafil). A more recent clinical evaluation of tadalafil enrolled 1112 men with a broad spectrum of severity and etiology for erectile dysfunction. 34 The study population had a mean age of 59 y and included men with hypertension, coronary artery disease, diabetes mellitus and depression. Tadalafil significantly increased most of the efficacy outcomes in a dosedependent manner. A unique aspect of the study examined the percentage of successful intercourse attempts over time after drug administration. Efficacy was maintained up to 36 h after dosing without diminishment, correlating with the longer half-life of tadalafil. Given that vardenafil has been shown to enhance erectile function after four half-lives in a conscious rabbit model, 36 it is likely that tadalafil would remain efficacious well beyond the measured 36 h time point.
Although direct head-to-head comparative clinical data from the same study are not currently available, data from studies using a single PDE 5 inhibitor suggest that differences in biochemical potency may be carried forward to the clinical setting (Figures 3 and 4) . This notion is verified by the range of dosages used clinically and the effective plasma concentrations achieved by each PDE 5 inhibitor. However, it should be noted that at the normally prescribed doses, the efficacy of all three PDE 5 inhibitors is similar. As discussed previously, the time window during which tadalafil remains efficacious is probably greater due to its prolonged half-life and the resulting elevation in plasma drug concentration.
Safety and tolerability of PDE 5 inhibitors
The safety and tolerability of sildenafil, vardenafil and tadalafil are dependent upon the tissue-specific distribution of phosphodiesterases, the selectivity or inherent cross-reactivity of each drug with phosphodiesterase subtypes (other than PDE 5) and biological action unrelated to phosphodiesterase inhibition. In general, sildenafil, vardenafil and tadalafil all have excellent selectivity for PDE 5. However, sildenafil is somewhat less selective against PDE 1 and PDE 6 (Table 3) . 18, 19 (E Gbekor, personal communication, 2002). Vardenafil is less selective for PDE 6, whereas tadalafil is least selective for PDE 11. These varying selectivity profiles may influence adverse event outcomes as 27 Goldstein et al, 29 Pryor, 30 and Hellstrom et al.
32 Figure 4 Clinical efficacy of PDE 5 inhibitors as assessed by global assessment question (GAQ). See Porst et al, 26, 31 Hatzichristou, 27 Goldstein et al, 29 Pryor, 30 and Hellstrom et al.
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PDE 5 -a survey NN Kim S16 ever larger numbers of patients are administered PDE 5 inhibitors. PDE 1 is mainly located in vascular smooth muscle, heart and brain, whereas PDE 6 is strictly localized in the retina. PDE 11 has a wide tissue distribution, including skeletal muscle, testes, prostate, breast and corpus cavernosum. 37, 38 While the gene for PDE 11 has been cloned and two different splice variants have been identified, 38, 39 little is known about its biological role(s) and the consequences of PDE 11 inhibition in the various tissues are difficult to predict. Adverse event profiles arising out of clinical trials have provided the most valuable information, thus far. The currently available clinical data suggest that none of the PDE 5 inhibitors cause serious adverse events. General assessments of cardiovascular function such as blood pressure measurements and electrocardiograms indicate that there are no clinically relevant adverse changes due to administration of sildenafil, vardenafil of tadalafil. 32, 33, 40 The most common adverse events for men taking PDE 5 inhibitors have been headache, cutaneous flushing, nasal congestion and dyspepsia. The occurrence of these adverse events was usually dose-dependent and mild to moderate in severity. The prevalence of three commonly reported adverse events in PDE 5 inhibitor studies is shown in Figure 5 . For comparative purposes, data for a single common dose (or the closest alternative) are given for each PDE 5 inhibitor. In addition to these common adverse events, approximately 1-11% of study participants taking varying doses of sildenafil reported visual disturbances such as changes in acuity, color or brightness. 40 For vardenafil, less than 2% of study participants reported visual changes and none of these indicated blue color vision. 32 It is unclear if any of the visual changes were treatment related, since other vardenafil studies report no abnormal visual disturbances. Similarly, no significant changes in color vision were reported by tadalafil study participants. Unique to tadalafil treatment are complaints of back pain, which tend to increase slightly at higher doses (4-9% for drug vs 0-5% for placebo). 25, 33, 34 The cause of the back pain remains unclear, although PDE 11 is suspected to play a role.
An additional concern regarding inhibition of PDE 11 has been that of testicular function. In a recent randomized, double-blind, placebo-controlled study, the effects of tadalafil on sperm characteristics were examined. 41 Tadalafil at the 20 mg dose was administered daily for 6 months to men who were healthy or had mild erectile dysfunction. Parameters of sperm morphology, motility, number and concentration were measured along with serum testosterone, luteinizing hormone and follicle stimulation hormone. Tadalafil was Goldstein et al, 29 Pryor, 30 and Hellstrom et al.
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found to have no significant effect on hormone levels or on the characteristics of sperm with the exception of attenuating a decrease in sperm motility. These data suggest that continual inhibition of PDE 11 has no detrimental effects on spermatogenesis or hormone levels. However, further studies are warranted to confirm and extend these findings.
Owing to the potential hypotensive action of PDE 5 inhibitors, all concomitant nitrate use is contraindicated. Potential interactions also exist with alpha-adrenergic blockers. In addition, since these PDE 5 inhibitors are predominantly degraded by the cytochrome P450 family of hepatic microsomal enzymes, use of drugs that significantly compromise this catabolic system (eg erythromycin, ketoconazole, itraconazole, cimetidine, saquinavir) may result in higher concentrations of PDE 5 inhibitors for prolonged periods of time, increasing the likelihood of adverse events. Similarly, patients over 65 y of age or those with hepatic or severe renal impairment may experience elevated levels of plasma PDE 5 inhibitors. Thus, the use of lower doses is deemed advisable in these patients.
Summary
The biochemical characterization of sildenafil, vardenafil and tadalafil indicates that these compounds are all potent and selective inhibitors of PDE 5. By virtue of the major role of PDE 5 in regulating cGMP metabolism in penile cavernosal tissue, this potency and selectivity on the molecular level translates to drugs that are highly efficacious and safe. Overall, sildenafil, vardenafil and tadalafil exhibit low adverse event profiles and are well tolerated by patients.
